We can readily understand why investors are attracted to unprofitable companies. For example, although Amazon.com ...

Swiss National Bank boosted its holdings in shares of 10x Genomics, Inc. (NASDAQ:TXG – Free Report) by 1.5% in the 4th quarter, HoldingsChannel.com reports. The institutional investor owned 188,400 ...

What a brutal six months it’s been for 10x Genomics. The stock has dropped 52.1% and now trades at $10.59, rattling many shareholders. This was partly due to its softer quarterly results and might ...

Bank of New York Mellon Corp lowered its stake in shares of 10x Genomics, Inc. (NASDAQ:TXG – Free Report) by 13.5% in the ...

10x Genomics stock crashed Thursday after the medtech reported preliminary third-quarter sales that widely missed Street ...

10X Genomics, Inc. is a life science technology company, which engages in building products to interrogate, understand and master biology. Its integrated solutions include single cell ...

Buy 10x Genomics with a 1-year target of $12.7, projecting 18% growth. Read here for more on TXG stock's biopharma potential ...

Explore 10x Genomics stock price, quotes, charts and forecasts with Benzinga. Stay updated on market trends for TXG. Life Science Company 10x Genomics Struggles With Profitability, Analyst Says ...

PLEASANTON, Calif., March 3, 2025 /PRNewswire/ — 10x Genomics (Nasdaq: TXG), a leader in single-cell and spatial biology, today provided an update on its patent litigation with Parse Biosciences.

10x Genomics stands as a pioneer in the life sciences sector, focusing on developing cutting-edge technologies that facilitate high-resolution biological analysis. Its key platforms, including ...

Whitaker, Chief Legal Officer of 10x Genomics. "We are pleased with this resolution on ATAC as we continue to defend the asserted Brenner patents on appeal." The company's litigation against Parse ...